What Happened?
Shares of medical device company Boston Scientific (NYSE: BSX) jumped 4.2% in the afternoon session after the company reported second-quarter financial results that surpassed Wall Street expectations and raised its full-year guidance. Boston Scientific announced net sales of $5.06 billion for the quarter, a significant 22.8% increase from the same period last year. This figure comfortably beat analysts' revenue forecasts of around $4.89 billion. The company's adjusted earnings per share (EPS) came in at $0.75, which was also higher than the consensus estimate of $0.72. The strong performance was driven by robust growth in its Cardiovascular segment, which saw sales jump 26.8%. Buoyed by these results, Boston Scientific increased its financial outlook for the full year. The company now projects full-year 2025 adjusted EPS to be between $2.95 and $2.99, an increase from its previous forecast. It also raised its expected sales growth to a range of 18% to 19% for the year.
After the initial pop the shares cooled down to $107.02, up 3.7% from previous close.
Is now the time to buy Boston Scientific? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Boston Scientific’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 3 months ago when the stock gained 8.5% on the news that the company reported first quarter 2025 results that beat analysts' sales and EPS expectations. Organic sales growth topped the company's own forecast and was led by a 25.6% surge in its Cardiovascular segment, a signal that demand in its largest business is accelerating. Looking ahead, its revenue guidance for next quarter exceeded Wall Street's estimates. Overall, we think this was a decent quarter with some key metrics above expectations.
Boston Scientific is up 19.7% since the beginning of the year, and at $107.02 per share, it is trading close to its 52-week high of $107.41 from June 2025. Investors who bought $1,000 worth of Boston Scientific’s shares 5 years ago would now be looking at an investment worth $2,785.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
